Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Gilead Hires Alessandro Riva to Lead Oncology R&D Efforts

By Ryan Bushey | January 5, 2017

Gilead Sciences has added a top cancer specialist to its executive ranks in order to bolster the company’s research and development efforts focusing on oncology.

Alessandro Riva will join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head, according to the official announcement.  He’ll leave his post at Novartis Oncology where he worked as the global head of oncology development.

Riva was responsible for the development of more than 20 cancer compounds while also working on regulatory approvals for new medicines targeting both solid and hematological malignancies throughout his 12 year tenure at the Swiss drug-maker.

“I am thrilled to welcome Alessandro, who brings a wealth of experience and expertise in hematology/oncology drug development and translational medicine,” said Dr. John McHutchison, Gilead’s Executive Vice President of Clinical Research in a statement. “His leadership and proven track record developing therapies across the spectrum of hematological malignancies and solid tumors will be instrumental as we continue to grow and advance our pipeline of novel therapeutics for people living with cancer.”

Riva’s expertise could be beneficial as Gilead seeks to grow its oncology unit to offset analyst forecasts predicting a decline in its lucrative hepatitis C franchise and overcome a series of setbacks in this field, reported Endpoints News.

Six studies of blood cancer drug Zydelig were halted amid safety concerns, which was followed by subpar data for experimental myelofibrosis drug momelotinib.

Riva’s best option could be using Gilead’s cash reserves to identify potential acquisitions and external licensing opportunities that will strengthen the firm’s cancer pipeline.

Gilead’s shares were up over 3 percent in mid-day trading.

Related Articles Read More >

5 R&D developments to keep an eye on this week: Solar crash and Trump’s energy pivot meets Musk’s rebellion
Mayo Clinic develops AI tool that can spot 9 dementia types with a single scan
Google DeepMind’s AlphaGenome AI predicts how non-coding DNA can drive disease
Top 10 drugs by patent volume: How biologics build ‘platform empires’ while small molecule create ‘patent thickets’
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE